U
URGN
Urogen Pharma
19.10
+1.07+5.93%After Hours: 18.78 -0.32 -1.68%18:43 04/08 EDT
OPEN/PREV CLOSE19.55/18.03
TODAY RANGE18.25-19.55
VOL817.18K
MARKET CAP929.83M
52 WEEK RANGE3.420-30.00
AVG VOL (3M)789.19K
% TURNOVER1.68%
TURNOVER--
P/E (TTM)-5.9873
% RANGE7.21%
EPS(TTM)-3.1901
P/E(FORWARD)-14.1481
P/B-8.7554
BVPS-2.1815
DIVIDEND--
P/S8.41
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP878.29M
SHARES OUTSTANDING48.68M
NEXT EARNINGS05/11-05/15
FREE FLOAT45.98M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·03/31 12:48
UroGen Pharma Is Maintained at Buy by D. Boral Capital
TipRanks·03/30 13:09
UroGen Pharma publishes results from ENVISION trial of Zusduri
TipRanks·03/13 12:16
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
TipRanks·03/09 00:28
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
Seeking Alpha·03/05 06:53
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
TipRanks·03/03 12:26
Guggenheim Sticks to Their Buy Rating for Urogen Pharma (URGN)
TipRanks·03/03 06:00
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
Seeking Alpha·03/02 17:58
UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline
Dow Jones·03/02 15:57
UroGen Pharma Is Maintained at Buy by D. Boral Capital
Dow Jones·03/02 15:57
UroGen Pharma Price Target Maintained With a $33.00/Share by D. Boral Capital
Benzinga·03/02 15:47
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $33 Price Target
TipRanks·03/02 13:36
UroGen Pharma Secures New $250 Million Term Loan
Same Industry
Name/Symbol
Change%
Price